JP2009544582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009544582A5 JP2009544582A5 JP2009518903A JP2009518903A JP2009544582A5 JP 2009544582 A5 JP2009544582 A5 JP 2009544582A5 JP 2009518903 A JP2009518903 A JP 2009518903A JP 2009518903 A JP2009518903 A JP 2009518903A JP 2009544582 A5 JP2009544582 A5 JP 2009544582A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- cell activator
- alkyl
- cell
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 7
- 229940126530 T cell activator Drugs 0.000 claims 17
- 210000004027 cell Anatomy 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 230000001225 therapeutic effect Effects 0.000 claims 11
- 125000003118 aryl group Chemical group 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 7
- 125000005466 alkylenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 6
- -1 epoxyalkyl Chemical group 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 150000001408 amides Chemical class 0.000 claims 4
- 150000001412 amines Chemical class 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002466 imines Chemical class 0.000 claims 4
- 150000002632 lipids Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 150000001767 cationic compounds Chemical class 0.000 claims 3
- 229910001411 inorganic cation Inorganic materials 0.000 claims 3
- 150000002892 organic cations Chemical class 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 230000001575 pathological effect Effects 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical compound N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 claims 2
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims 2
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 claims 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 2
- 108091034117 Oligonucleotide Proteins 0.000 claims 2
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 claims 2
- 125000003172 aldehyde group Chemical group 0.000 claims 2
- 229940062527 alendronate Drugs 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- YKAYCWPQDPILSA-UHFFFAOYSA-N bromohydrin pyrophosphate Chemical group BrCC(O)(C)CCOP(O)(=O)OP(O)(O)=O YKAYCWPQDPILSA-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 125000002843 carboxylic acid group Chemical group 0.000 claims 2
- 239000005515 coenzyme Substances 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 150000002118 epoxides Chemical class 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 229930195729 fatty acid Natural products 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 229930003935 flavonoid Natural products 0.000 claims 2
- 150000002215 flavonoids Chemical class 0.000 claims 2
- 235000017173 flavonoids Nutrition 0.000 claims 2
- 229960000304 folic acid Drugs 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 150000004676 glycans Chemical class 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000005843 halogen group Chemical group 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000003944 halohydrins Chemical class 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 229940015872 ibandronate Drugs 0.000 claims 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims 2
- 229960000367 inositol Drugs 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 150000002772 monosaccharides Chemical class 0.000 claims 2
- 150000002825 nitriles Chemical class 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000002777 nucleoside Substances 0.000 claims 2
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
- 229920001542 oligosaccharide Polymers 0.000 claims 2
- 150000002482 oligosaccharides Chemical class 0.000 claims 2
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical group NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 claims 2
- 229940046231 pamidronate Drugs 0.000 claims 2
- 229960004838 phosphoric acid Drugs 0.000 claims 2
- 229920001282 polysaccharide Polymers 0.000 claims 2
- 239000005017 polysaccharide Substances 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229940089617 risedronate Drugs 0.000 claims 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 2
- 150000003457 sulfones Chemical class 0.000 claims 2
- 150000003462 sulfoxides Chemical class 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 150000003573 thiols Chemical class 0.000 claims 2
- 229940088594 vitamin Drugs 0.000 claims 2
- 239000011782 vitamin Substances 0.000 claims 2
- 229930003231 vitamin Natural products 0.000 claims 2
- 235000013343 vitamin Nutrition 0.000 claims 2
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 2
- 229960004276 zoledronic acid Drugs 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 229910052794 bromium Inorganic materials 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001768 cations Chemical class 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 CC(*C(*)(*)*=C(*)*)P(BCP(*)(N[*+])=O)([*+])=N Chemical compound CC(*C(*)(*)*=C(*)*)P(BCP(*)(N[*+])=O)([*+])=N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06291146A EP1878440A1 (en) | 2006-07-13 | 2006-07-13 | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta cell activator compounds |
| US92420807P | 2007-05-03 | 2007-05-03 | |
| PCT/EP2007/057217 WO2008006895A2 (en) | 2006-07-13 | 2007-07-12 | Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009544582A JP2009544582A (ja) | 2009-12-17 |
| JP2009544582A5 true JP2009544582A5 (https=) | 2010-08-26 |
Family
ID=37708304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009518903A Pending JP2009544582A (ja) | 2006-07-13 | 2007-07-12 | γδＴ細胞活性化物質を使用して治療用抗体の効率を増大させる方法および組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090304688A1 (https=) |
| EP (2) | EP1878440A1 (https=) |
| JP (1) | JP2009544582A (https=) |
| AU (1) | AU2007274295A1 (https=) |
| CA (1) | CA2658222A1 (https=) |
| WO (1) | WO2008006895A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2150258A2 (en) * | 2007-06-01 | 2010-02-10 | Innate Pharma S.A. | Improved methods of using phosphoantigens together with interleukin-2 for the treatment of cancer |
| US8735624B2 (en) | 2008-09-10 | 2014-05-27 | Innate Pharma | Polymorphic form of CHDMAPP, method of preparation thereof, and pharmaceutical composition comprising same |
| US20100183558A1 (en) | 2008-10-17 | 2010-07-22 | Zhennan Lai | Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules |
| KR101940430B1 (ko) | 2014-08-07 | 2019-01-18 | 가꼬우호우징 효고 이카다이가쿠 | Il-18과 분자 표적 항체를 병용하는 암 치료약 |
| US10501541B2 (en) | 2015-01-27 | 2019-12-10 | Lava Therapeutics B.V. | Single domain antibodies targeting CD1d |
| EP3319631A4 (en) | 2015-07-08 | 2019-01-09 | American Gene Technologies International Inc. | HIV PREMUNICATION AND IMMUNOTHERAPY |
| US10137144B2 (en) | 2016-01-15 | 2018-11-27 | American Gene Technologies International Inc. | Methods and compositions for the activation of gamma-delta T-cells |
| CN116064678A (zh) | 2016-01-15 | 2023-05-05 | 美国基因技术国际有限公司 | 用于活化γ-δT细胞的方法和组合物 |
| WO2017139065A1 (en) | 2016-02-08 | 2017-08-17 | American Gene Technologies International Inc. | Hiv vaccination and immunotherapy |
| WO2017156311A2 (en) | 2016-03-09 | 2017-09-14 | American Gene Technologies International Inc. | Combination vectors and methods for treating cancer |
| EP3468617A4 (en) | 2016-06-08 | 2020-01-22 | American Gene Technologies International Inc. | SYSTEM FOR THE NON-INTEGRAL VIRAL ISSUE AND PROCEDURE RELATING TO IT |
| AU2017292582C1 (en) | 2016-07-08 | 2021-11-11 | American Gene Technologies International Inc. | HIV pre-immunization and immunotherapy |
| EP3487507A4 (en) | 2016-07-21 | 2020-04-08 | American Gene Technologies International, Inc. | VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE |
| US11820999B2 (en) | 2017-04-03 | 2023-11-21 | American Gene Technologies International Inc. | Compositions and methods for treating phenylketonuria |
| JP2020524996A (ja) | 2017-06-16 | 2020-08-27 | アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド | ヒトガンマデルタｔ細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 |
| TWI687227B (zh) * | 2017-10-03 | 2020-03-11 | 生倍科技股份有限公司 | 用於t細胞免疫療法之組合及其用途 |
| AU2019344300A1 (en) | 2018-09-19 | 2021-04-22 | LAVA Therapeutics N.V. | Dual acting CD1D immunoglobulin |
| CA3114292A1 (en) * | 2018-09-27 | 2020-04-02 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| US11352646B2 (en) | 2018-11-05 | 2022-06-07 | American Gene Technologies International Inc. | Vector system for expressing regulatory RNA |
| CN109529050A (zh) * | 2018-12-07 | 2019-03-29 | 广州市妇女儿童医疗中心 | Vγ9δ2T细胞、治疗肺癌的药物ZOL和hMSH2协同作用的应用 |
| KR20230042035A (ko) | 2020-07-08 | 2023-03-27 | 라바 테라퓨틱스 엔.브이. | Psma와 감마-델타 t 세포 수용체에 결합할 수 있는 항체 |
| US20240148827A1 (en) * | 2021-03-11 | 2024-05-09 | The Methodist Hospital | Methods and Compositions for Treatment of Disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5639653A (en) | 1993-07-19 | 1997-06-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy | Method for proliferating Vγ2Vδ2 T cells |
| FR2715660A1 (fr) | 1994-01-28 | 1995-08-04 | Centre Nat Rech Scient | Composés organo-phosphorés activateurs des lymphocytes Tgammadelta, procédé pour préparer et/ou isoler et/ou caractériser ces composés, compositions et utilisations pharmaceutiques. |
| FR2782721B1 (fr) * | 1998-09-01 | 2000-11-03 | Inst Nat Sante Rech Med | Nouveaux composes phosphohalohydrines, procede de fabrication et applications |
| WO2005054258A2 (en) * | 2003-12-02 | 2005-06-16 | Innate Pharma | New class of gamma delta t cells activators and use thereof |
| WO2005067635A2 (en) * | 2004-01-06 | 2005-07-28 | Hava Corp. | Telephone with automatic switching between cellular and voip networks |
| ATE419008T1 (de) * | 2004-04-26 | 2009-01-15 | Innate Pharma | Adjuvante zusammensetzung und anwendungsverfahren dafür |
| WO2006067635A2 (en) * | 2004-12-20 | 2006-06-29 | Innate Pharma S.A. | USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT |
-
2006
- 2006-07-13 EP EP06291146A patent/EP1878440A1/en not_active Withdrawn
-
2007
- 2007-07-12 EP EP07765821A patent/EP2040750A2/en not_active Withdrawn
- 2007-07-12 JP JP2009518903A patent/JP2009544582A/ja active Pending
- 2007-07-12 CA CA002658222A patent/CA2658222A1/en not_active Abandoned
- 2007-07-12 AU AU2007274295A patent/AU2007274295A1/en not_active Abandoned
- 2007-07-12 US US12/307,047 patent/US20090304688A1/en not_active Abandoned
- 2007-07-12 WO PCT/EP2007/057217 patent/WO2008006895A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009544582A5 (https=) | ||
| TWI811812B (zh) | 磷脂化合物及其用途 | |
| JP2019511491A5 (https=) | ||
| CN1305485A (zh) | 单体,寡聚和多聚科诺威纳格尔缩合产物 | |
| JP2017518302A5 (https=) | ||
| EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
| Majer et al. | Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA) | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| JP6525956B2 (ja) | テロメラーゼ媒介性テロメア変容化合物 | |
| JP2010501584A5 (https=) | ||
| JP2012505836A5 (https=) | ||
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| ES2887042T1 (es) | Moduladores del receptor S1P para el tratamiento de la esclerosis múltiple | |
| JP2017530109A5 (ja) | 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護のための組成物及びキット | |
| MX2012012225A (es) | Profármacos de agentes tearapéuticos de liberación de óxido nítrico. | |
| BR112015003778B1 (pt) | Profármaco de tenofovir, composição farmacêutica, e seus usos | |
| JP2020530007A5 (https=) | ||
| JP2013534248A5 (https=) | ||
| RU2011123700A (ru) | Нонапептид с противоопухолевой активностью | |
| JP2014519507A5 (https=) | ||
| FI3065763T4 (fi) | Il-22-dimeerin käyttö lääkkeen valmistamisessa suonensisäistä antoa varten | |
| CY1120852T1 (el) | Φαρμακευτικη συνθεση η οποια περιλαμβανει ιβουπροφαινη, τραμαδολη και ενα βασικο αμινοξυ, μεθοδος παρασκευης αυτης και χρηση της ιδιας | |
| RU2016111704A (ru) | Производные дезоксинойиримицина и способы их применения | |
| RU2013156939A (ru) | Способ лечения лихорадки денге | |
| JP2013522231A5 (https=) |